Fear of Recurrence and Health Anxiety Aren’t the Same Thing. The Difference Matters More Than You’d Think

For many people who survive colorectal cancer, the fear that it might come back does not simply fade with time. For some, it hardens into something more persistent and more complicated than ordinary worry. A new study published in June 2026 in the journal Cancer Survivorship Research suggests that clinicians and researchers have been treating two distinct psychological conditions as if they were one, and that this confusion may be quietly undermining treatment outcomes.

Clinical Fear of Recurrence in Long-Term Colorectal Survivors

The study by Ingeman and colleagues focused specifically on long-term survivors, defined as people who were at least five years out from their colorectal cancer diagnosis with no evidence of recurrence. At that point, the objective risk of cancer returning is relatively low. Yet a meaningful proportion of survivors in the cohort still reported persistent, preoccupying fears about their health. Among those assessed, 38 participants met criteria for clinical fear of cancer recurrence (FCR) only, while 44 met criteria for both clinical FCR and health anxiety (HA). Only five met criteria for HA alone.

Clinical FCR is defined by high preoccupation and worry that persists for more than three months, alongside heightened vigilance to bodily symptoms. It is different from the natural anxiety that follows a cancer diagnosis. A meta-analysis of more than 9,000 cancer survivors found that 58.8% experience some level of FCR, with 19.2% reaching the threshold for severe fear. Among long-term colorectal survivors specifically, the rate of clinical FCR drops to around 5.3%, suggesting that most people do find their fears diminish over time. Those who do not may need targeted help.

Why Confusing These Two Conditions Could Hurt Patients

Health anxiety, classified under hypochondriasis in the ICD-11 and as illness anxiety disorder or somatic symptom disorder in the DSM-5, shares obvious surface features with FCR. Both involve illness-related worry and heightened attention to physical sensations. But their underlying mechanisms differ in important ways, and those differences have direct implications for treatment.

Participants in the comorbid FCR-plus-HA group showed a notably more complex clinical picture. Among this group, 44% reported that their illness worries had actually predated their cancer diagnosis, compared with just 5.3% in the FCR-only group. That is a striking gap. It suggests that for nearly half the people in the comorbid group, cancer did not create the anxiety so much as give it a new object. Only 2.3% of people in the comorbid group reported worries limited to colorectal cancer, versus 42.1% of those with FCR only. The comorbid group also had significantly higher levels of depression (p=0.005), anxiety (p<0.001), and general emotional distress (p=0.005).

Research in breast cancer populations has already documented how FCR raises the risk of depression and erodes quality of life over the long term. The implication of the new study is that survivors carrying both FCR and HA face an even steeper psychological burden, one that standard FCR interventions may not fully address.

How the Researchers Assessed Both Conditions

The team drew on two sources of data: a national cohort and a randomized controlled trial of a therapist-guided, internet-delivered intervention called TG-iConquerFear. This program delivers six modules over ten weeks, covering attention training, metacognitive awareness, acceptance, detached mindfulness, and values-based goal setting. Participants were assessed before the intervention using both self-report questionnaires and clinical interviews.

The clinical interviews were conducted by psychologists with five to twenty years of experience in health anxiety assessment and treatment. They used a modified version of the Research Interview for Functional Somatic Disorders to diagnose HA, applying diagnostic criteria from Fink and colleagues that require obsessive illness rumination as a core symptom. FCR was rated by the same psychologists based on the persistence, preoccupation, hypervigilance, and functional impact of illness-related worries.

The use of expert clinical interviews alongside validated questionnaires, specifically the 42-item Fear of Cancer Recurrence Inventory (FCRI) and the Whiteley-6-R for illness worries, is one of the study's methodological strengths. A scoping review on FCR and health anxiety in breast cancer survivorship previously highlighted that these two constructs are often conflated in research because they share measurement tools, making this kind of structured clinical differentiation especially valuable.

Open Questions About Sample Size and Generalizability

The study's conclusions come with important caveats. The sample sizes are small: 38 participants with FCR only, 44 with comorbid FCR and HA, and only 5 with HA alone. Treatment outcome analyses were even more constrained, covering just 12 people in the FCR-only group and 22 in the comorbid group. The formal inter-rater reliability of the clinical interviews was not assessed, partly because sessions were not audio-recorded.

The sampling strategy also skewed toward individuals with elevated FCR, which means the findings may not generalize well to the broader population of colorectal cancer survivors. The tentative finding that FCR-only individuals appeared to benefit more from TG-iConquerFear than those with comorbid HA is intriguing, but the missing data in treatment outcome analyses make it impossible to draw firm conclusions at this stage. This is preliminary research pointing toward a hypothesis, not a settled answer.

What Distinguishing FCR From Health Anxiety Could Change

If the pattern holds up in larger studies, the practical implications are significant. Effective FCR treatments focus on reframing uncertainty, scheduling structured worry time, mindfulness, and managing health-seeking behaviors. Typical cognitive behavioral approaches for health anxiety, including exposure to feared illness stimuli, take a different route. The authors suggest that applying FCR-focused therapy to someone who actually has comorbid HA may simply not target the right mechanisms.

CBT-based interventions for fear of recurrence have shown promise in face-to-face and web-based formats, but the field has not yet systematically screened participants for underlying health anxiety before assigning them to these programs. This study argues that screening matters: knowing whether a survivor's fears are cancer-specific or part of a broader anxiety about illness could determine which treatment pathway they are offered.

Beyond treatment matching, the authors raise a point about language and stigma. Framing persistent post-cancer worry as a potentially diagnosable psychological condition, rather than a proportionate response to having had cancer, can help destigmatize the experience and open pathways to care. For survivors five or more years out from diagnosis who still cannot stop worrying, that framing may itself be a relief.

Evidence rating

INVESTIGATIONAL — 51/100

Caveats:

• Very small subgroup sizes (n=38 FCR-only, n=44 comorbid, n=5 HA-only) limit statistical power and generalizability.
• Treatment outcome comparisons are descriptive only — no formal statistical testing was conducted on those subgroups.
• Sample was enriched for elevated FCR and not randomly selected, so prevalence estimates may not reflect the broader survivor population.
• Funding source was not disclosed.

Secondary analysis of a national cohort and RCT drawing on clinical interviews and self-report measures in a small, FCR-enriched sample of colorectal cancer survivors (≥5 years post-diagnosis). The study is cross-sectional for its primary comparisons and shows associations, not causal relationships; treatment outcome analyses are descriptive only, with no formal between-group testing and substantial missing data. Findings have not been independently replicated.

References

1. Katrine Ingeman, Johanne D. Lyhne, Per Fink, Allan “Ben” Smith, Lisbeth Frostholm, Tina Birgitte Wisbech Carstensen (2026). Overlap and distinction between fear of cancer recurrence and health anxiety in long-term colorectal cancer survivors. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02058-6
2. What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta‐analysis – PMC. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814704/
3. Thi Xuan Mai Tran, So-Youn Jung, Eun-Gyeong Lee, et al. (2022). Fear of Cancer Recurrence and Its Negative Impact on Health-Related Quality of Life in Long-term Breast Cancer Survivors. Cancer Research and Treatment. https://doi.org/10.4143/crt.2021.835
4. Christine Maheu, Mina Singh, Wing Lam Tock, et al. (2021). Fear of Cancer Recurrence, Health Anxiety, Worry, and Uncertainty: A Scoping Review About Their Conceptualization and Measurement Within Breast Cancer Survivorship Research. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2021.644932
5. Clizia Cincidda, Silvia Francesca Maria Pizzoli, Gabriella Pravettoni (2022). Remote Psychological Interventions for Fear of Cancer Recurrence: Scoping Review. JMIR Cancer. https://doi.org/10.2196/29745